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Defining the Schistosoma 
haematobium kinome enables the 
prediction of essential kinases as 
anti-schistosome drug targets
Andreas J. Stroehlein1, Neil D. Young1, Aaron R. Jex1, Paul W. Sternberg2, Patrick Tan3,4, 
Peter R. Boag5, Andreas Hofmann1,6 & Robin B. Gasser1
The blood fluke Schistosoma haematobium causes urogenital schistosomiasis, a neglected tropical 
disease (NTD) that affects more than 110 million people. Treating this disease by targeted or 
mass administration with a single chemical, praziquantel, carries the risk that drug resistance will 
develop in this pathogen. Therefore, there is an imperative to search for new drug targets in S. 
haematobium and other schistosomes. In this regard, protein kinases have potential, given their 
essential roles in biological processes and as targets for drugs already approved by the US Food 
and Drug Administration (FDA) for use in humans. In this context, we defined here the kinome of S. 
haematobium using a refined bioinformatic pipeline. We classified, curated and annotated predicted 
kinases, and assessed the developmental transcription profiles of kinase genes. Then, we prioritised 
a panel of kinases as potential drug targets and inferred chemicals that bind to them using an 
integrated bioinformatic pipeline. Most kinases of S. haematobium are very similar to those of its 
congener, S. mansoni, offering the prospect of designing chemicals that kill both species. Overall, this 
study provides a global insight into the kinome of S. haematobium and should assist the repurposing 
or discovery of drugs against schistosomiasis.
Schistosomiasis is a neglected tropical disease caused by blood flukes of the genus Schistosoma (phylum 
Platyhelminthes; class Trematoda)1,2. The three main species, Schistosoma haematobium, S. mansoni and 
S. japonicum, affect around 230 million people worldwide1. The former two flukes predominate, infecting 
almost 200 million humans in sub-Saharan Africa alone3,4. S. haematobium causes the urogenital form 
of this disease, and S. mansoni leads to hepato-intestinal illness1. These flukes have a complex life cycle, 
involving aquatic snails (family Planorbidae) as intermediate hosts. In freshwater, the infective larvae 
(cercariae) leave the snail and infect the definitive, human host by penetrating skin. Upon penetration, 
the cercariae lose their tails, and the larvae (schistosomules) migrate through the circulatory system and 
lung to the portal system, after which they mature and mate. Subsequently, paired adult worms migrate to 
their site of predilection and start to reproduce. S. mansoni adults live mainly in the portal system and/or 
the mesenteric venules of the small intestine, where they produce eggs that pass through the intestinal 
wall and are excreted in faeces. S. haematobium adults usually inhabit the blood vessels around the uri-
nary bladder and genital system; here, the parasite produces eggs that pass through the bladder wall and 
are released in urine. Once eggs are released into freshwater, they immediately hatch to release miracidia 
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(free-living larvae), which then invade a molluscan intermediate host1. S. haematobium infects snails of 
the genus Bulinus5, whereas S. mansoni prefers snails of the genus Biomphalaria6.
Disease in humans is precipitated by eggs that become entrapped in tissues, where they induce a 
chronic immune-mediated response, followed by granulomatous changes and ensuing fibrosis1. Eggs 
of S. mansoni become lodged mainly in the liver and intestinal wall, leading to egg-induced hepatitis, 
enteritis and/or associated complications7. In contrast, S. haematobium eggs are deposited mainly in 
the vasculature of the urinary bladder, ureter and/or genital tract (particularly in female individuals), 
although they can be disseminated to other sites in the body. Entrapped eggs induce considerable inflam-
mation and subsequent fibrosis and/or calcification of the bladder. In addition, chronic S. haematobium 
infection can increase the risk of secondary bacterial infections7, is a predisposing factor for HIV/AIDS8 
and can, together with other factors, induce malignant bladder cancer9. As there is no effective vaccine 
against schistosomiasis, current treatment relies on a single drug, praziquantel10. With increased efforts 
to control this disease by mass treatment, the possibility of praziquantel resistance developing is a serious 
concern11,12. Thus, there is a need for sustained research toward developing alternative chemotherapeutic 
compounds against schistosomiasis.
Recent research efforts to identify new molecular targets for chemotherapeutic intervention have 
focused on protein kinases13,14, because they are involved in signalling cascades of essential regulatory 
and developmental processes15–17, particular kinase groups have relatively conserved structures18, and 
also because drugs targeting these enzymes in humans have shown particular potential for the treat-
ment of cancers and other diseases19,20. Protein kinases are enzymes (transferases) that phosphorylate a 
substrate by transferring a phosphoryl group from an energy-rich molecule, such as adenosine triphos-
phate (ATP), to a target protein. This phosphorylation induces a modification of the substrate, leading 
to changes in conformation and activity21. Substrates are phosphorylated at an amino acid residue that 
has a free hydroxyl group. Kinases can be subdivided into serine/threonine-phosphorylating kinases 
(STKs), tyrosine-phosphorylating kinases (TKs) and kinases that phosphorylate either of these residues 
(called ‘dual-specificity’ or ‘hybrid’ kinases). The conserved, catalytic domain of kinases is a protein fold 
consisting of an amino-terminal lobe comprised of β -strands and a carboxy-terminal lobe that contains 
α -helices22. A polypeptide linker functions as a hinge and connects the two lobes, allowing for rotation. 
This lobe structure forms a catalytic cleft for substrate and ATP binding15,22,23.
Eukaryotic protein kinases (ePKs) represent the largest class of enzymes that share the same pro-
tein kinase-like (PKL) fold24. Kinases that have catalytic activity but are not structurally similar to the 
PKL fold are classified as atypical kinases (aPKs)15. Protein kinases can be assigned to groups, families 
and subfamilies based on sequence similarity in their catalytic domains and the presence of accessory 
domains. The established classification scheme for kinases (http://kinase.com/kinbase)16 is based on that 
originally proposed by Hanks and Hunter23, and defines nine ePK groups.
Recognising their essential role in a range of regulatory processes and relatively conserved structure 
and function25–27, more than 20 ePKs have been investigated experimentally in S. mansoni13,25. Some 
of these kinases have been shown to assume essential functions in the parasite17,28–31. For example, the 
targeting of multiple receptor kinases of S. mansoni with a single inhibitor led to a fatal impact on 
schistosome morphology and physiology32. The fact that human protein kinases are involved in cancer 
and numerous compounds which inhibit these enzymes are available and approved for therapeutic use 
offers a unique prospect of repurposing such chemicals to schistosomes25. In this context, the in silico 
prediction of the kinome of S. mansoni provides a basis for the investigation of schistosome kinases as 
drug targets33.
In contrast to the situation for S. mansoni, there is no detailed information on the kinome of S. hae-
matobium or any other schistosome. Given that S. haematobium is the causative agent of schistosomia-
sis in approximately two thirds of all humans infected by schistosomes and therefore has a substantial 
socioeconomic impact, in terms of disability-adjusted life years and morbidity4, there is a major need 
to work toward identifying drug targets in S. haematobium and designing new treatments34,35. In the 
present study, we defined the kinome of S. haematobium. Employing the S. mansoni kinome as a refer-
ence33, we: (i) curated the full complement of predicted kinases of S. haematobium using a comparative 
genomic-phylogenetic approach; (ii) assessed levels of transcription of genes encoding these kinases in 
the adult and egg stages of S. haematobium, and (iii) prioritised a panel of kinases as potential drug 
targets as well as chemicals inferred to bind to them using an integrated bioinformatic pipeline. We 
discuss the findings in the context of drug discovery and with regard to the distinctive biologies of S. 
haematobium and S. mansoni.
Results
The S. haematobium kinome. Here, we employed an integrative bioinformatic pipeline (Fig.  1). 
First, we predicted 223 kinases in the S. haematobium genome, 111 and 93 of which could be assigned 
to subfamilies and families, respectively; 10 could be assigned exclusively to a group, and nine remained 
unclassified. Subsequently, we identified 46 additional kinase sequences. Following this curation, the 
number of unclassified sequences decreased to four, and an improved classification of kinases into sub-
families (n = 134), families (n = 129) and groups (n = 2) was achieved (Fig. 2; Supplementary Table 1). 
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Thus, the curated S. haematobium genome was inferred to encode 269 kinases, including both ePKs and 
PKLs.
A total of 261 ePKs representing all nine major kinase groups were identified in S. haematobium (Fig. 2; 
Supplementary Table 1). The largest group represented CMGCs (n = 51), including 17 cyclin-dependent 
kinases (CDKs), four CDK-like kinases (CDKLs), 10 mitogen-activated protein kinases (MAPKs), 
11 dual-specificity tyrosine-regulated kinases (DYRKs), four glycogen synthase kinases (GSKs), two 
CDC-like kinases (CLKs), and one member of each of the families CK2, RCK and SRPK. The second 
largest group was CAMK, representing 41 kinases including CAMKs, CAMK-related kinases, MARKs 
and death-associated protein kinases (DAPKs). Only slightly smaller was the ‘Other’ group, which 
included 40 kinases representing 20 families that do not belong to any of the eight other ePK groups; 
this group included NEK, AUR (Aurora kinase), BUD32, HASPIN, two Polo-like kinases (PLKs), PEK 
(pancreatic eIF-2alpha kinase), SCY1 and ULK (Unc-51-like kinase). The AGC group represented 39 
kinases, including the cyclic nucleotide-dependent kinase families PKA (n = 6) and PKG (n = 4), and 
PKCs (n = 5), RSKs (n = 5) and DMPKs (n = 7). Of the 31 members of the TK group, 13 were receptor 
tyrosine kinases (RTKs), including epidermal growth factor receptors (EGFRs), fibroblast growth factor 
receptors (FGFRs), insulin receptors (INSRs or IRs) and two venus kinase receptors (VKRs). The other 
18 members were cytoplasmic tyrosine kinases (CTKs) and were assigned to 11 families (ABL, ACK, 
CSK, FAK, FER, RYK, SEV, SYK, TEC, TRK and SRC). The STE group contained 18 members of the 
STE20 family (MAP4Ks), two STE11 kinases (MAP3Ks) and six STE7 family members (MAP2Ks). The 
20 representatives of the TKL group belonged to the families STKR (n = 7), MLK (n = 6), RAF (n = 3), 
LRRK (n = 1) and LISK (n = 3). We also identified nine kinases belonging to the CK1 group, including 
three members of the Tau tubulin kinase family (TTBK) and one vaccinia-related kinase (VRK). Finally, 
with only three members, the receptor guanylate cyclases (RGCs) represented the smallest group of ePKs 
in the S. haematobium kinome.
In addition to ePKs, we identified four PKLs: two right open reading frame kinases, Sh-RIOK-1 
(A_06019) and Sh-RIOK-2 (A_01816), and two representing the ABC1 family (A_02560 and A_01324). 
The S. haematobium genome also encodes four unclassified serine/threonine kinases, to which we 
assigned the following annotations based on similarity searches against the protein database Swiss-Prot: 
A_05753 - Cell cycle serine/threonine-protein kinase CDC5; A_08069 - Kinase suppressor of Ras 1 
(KSR); C_01296 - Serine/threonine-protein kinase WNK1; Sh_Smp_017900.1 - Ribosomal protein S6 
kinase (RSK).
Figure 1. Bioinformatic pipeline used to characterize and curate kinases in Schistosoma haematobium. 
In step 1, we predicted and classified kinases in S. haematobium. In steps 2–3, additional sequences were 
identified employing the proteome51,88 and kinome33 inferred from the S. mansoni genome; incomplete or 
missing sequences were complemented using orthologous full-length sequences, which resulted in the final 
set of predicted kinase sequences. In steps 4 and 5, the catalytic domains in the kinase sequences were 
identified using trematode-specific HMMs for individual kinase groups, and then aligned (according to 
group) for subsequent phylogenetic analysis. In step 6, all kinases identified were functionally annotated 
employing SwissProt, KEGG and InterProScan databases.
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All remaining kinase sequences (n = 265) were assigned to families and/or subfamilies, except for two 
sequences (A_03674 and A_04152) that could be classified only to a group level (i.e. CAMK and STE, 
respectively). In a phylogenetic analysis, sequence A_03674 clustered with A_07692 (predicted PKD 
kinase), albeit with a low nodal support (61%; Supplementary Fig. 2), and thus could not be assigned 
with confidence to any particular family. The homolog of sequence A_04152 (STE family member) in S. 
mansoni (Smp_146290.1) has been classified previously as a STE7 kinase33, but, according to the present 
analysis, it clustered with a kinase of the STE20 family and FRAY subfamily with 72% nodal support 
(Supplementary Fig. 6). Thus, sequence A_04152 was not classified to a family or subfamily level.
For 267 of the 269 kinases defined in S. haematobium, orthologs were identified in S. mansoni based 
on a comparative genomic approach and subsequent phylogenetic analyses. For two S. haematobium 
kinase sequences, no ortholog was found, in spite of exhaustive searching of the S. mansoni genome 
(A_01970; CMGC/MAPK/ERK7 and A_07508; CMGC/DYRK/DYRK2), suggesting their uniqueness to 
S. haematobium.
A comparison of the kinomes of S. haematobium and S. mansoni revealed a high overall sequence 
identity (82–92%), similarity (87–94%) and a relatively conserved length (0–7% difference) between pairs 
of kinases (Table 1). The degree of sequence similarity among individual kinase groups differed consider-
ably, with kinases from the groups CK1 and RGC, and unclassified and PKL kinases, being, on average, 
more dissimilar compared with the other groups (Table 1). A pairwise sequence comparison of kinases 
of S. haematobium with human homologs revealed an average sequence similarity ranging from 60.9% 
(PKL) to 76.3% (CK1) for kinases that could be classified. For unclassified kinase sequences, we observed 
low sequence identity (35.1% on average) to their closest human homologs.
Figure 2. Phylogenetic analysis of eukaryotic protein kinases (ePKs) of Schistosoma haematobium 
and S. mansoni. Following the alignment of amino acid sequences representing individual kinase groups, 
phylogenetic trees were constructed. High resolution figures of individual trees including nodal support 
values and sequence identifiers are given in Supplementary Figs 2–9.
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Subsequent phylogenetic analyses of ePKs of both S. haematobium and S. mansoni supported the 
orthology found between pairs of kinases of these two species. With the exception of the Polo-like 
kinase Sh-SAK, and representatives of the ULK, SCY1, PKA and CAMK1 families/subfamilies (Fig.  2; 
Supplementary Figs 2–4), orthologous sequences formed pairs in individual trees (Fig. 2; Supplementary 
Figs 1–11), consistent with their classification using an approach based on hidden Markov models 
(HMMs). Seven kinase sequences were excluded from phylogenetic analysis, because the catalytic domain 
of one or both representatives of the orthologous pair did not match the trematode-specific HMM. Six 
of these sequences were members of the family SCY1 (A_01858, Smp_176440.1 and Sh_Smp_156890.1) 
or HASPIN (Smp_Sh_A_07473, Sh_Smp_158950.1 and Smp_158950.1), which are part of the ‘Other’ 
kinase group. The seventh sequence (Smp_Sh_A_06810) was a member of the STE group, STE11 family 
and ASK subfamily.
Taken together, the 269 protein kinases of S. haematobium and 267 orthologs in S. mansoni were 
shown to represent all nine recognised kinase groups, 88 families and 79 subfamilies. However, we did 
not detect representatives of 19 kinase families and subfamilies (Table  2) in these two schistosomes 
(Lophotrochozoa; Protostomia) that are present in members of both the Ecdysozoa (Protostomia, rep-
resented by Caenorhabditis elegans and Drosophila melanogaster) and Deuterostomia (represented by 
Homo sapiens). Finally, we functionally annotated S. haematobium kinase sequences identified herein 
and linked them to 20 conserved functional categories (Fig.  3; Supplementary Table 1). Most kinases 
were predicted to have functional roles in signal transduction, cell communication, cell growth and the 
immune and/or nervous systems (Fig. 3; Supplementary Table 1).
Transcription profiles. Following the curation and annotation of kinase sequences, we assessed tran-
scription levels of respective genes in different developmental stages and genders of S. haematobium 
(adult male, adult female and egg). Of the 274 sequences encoding kinases identified in S. haematobium, 
214 were transcribed in all three stages (Fig. 4). By contrast, 13 kinase genes were transcribed exclusively 
in the male and egg stages, 21 kinase genes were uniquely transcribed in the two adult stages, and one 
gene was transcribed in the female and egg stages, to the exclusion of the male stage (Fig. 4). One and 
eight kinase genes were transcribed exclusively in the egg and male stages, respectively. Among the eight 
male-specific genes were orthologs of the testis-expressed gene 14 (tex-14, Sh_Smp_131630.1_p1) and a 
gene coding for an atrial natriuretic peptide receptor (A_02682), a kinase belonging to the RGC group 
that regulates cardiovascular and body fluid homeostasis36. For 16 kinase genes, there was no evidence 
of transcription in any of the life cycle stages studied here (Fig. 4; Supplementary Table 2).
We also assessed transcription levels for the four unclassified S. haematobium kinase genes. For the 
sequence A_05753, we did not observe transcription in any of the life stages studied; A_08069 was lowly 
transcribed in the adult female only (TPM: 0.06) and C_01296 was moderately transcribed in both adult 
Kinase 
groupa
Length ratio 
Sh/Sm [SD]
S. mansoni 
% identity 
[SD]
S. mansoni 
% similarity 
[SD]
H. sapiens 
% identity 
[SD]
H. sapiens 
% similarity 
[SD]
CMGC 1.00 [0.08] 91.87 [6.10] 94.42 [4.96] 61.04 [8.93] 75.91 [7.15]
CAMK 1.00 [0.08] 87.89 [8.48] 91.48 [6.55] 54.57 [13.91] 71.31 [10.79]
AGC 0.99 [0.19] 91.20 [5.91] 93.78 [4.94] 52.40 [13.22] 68.66 [11.15]
Other 0.98 [0.17] 87.18 [8.46] 90.28 [7.77] 43.54 [12.06] 62.11 [10.87]
TK 0.99 [0.11] 87.66 [8.18] 91.12 [6.92] 45.74 [6.50] 63.68 [6.46]
STE 1.04 [0.22] 90.75 [6.89] 93.21 [6.22] 56.94 [12.14] 72.62 [10.73]
TKL 1.01 [0.08] 88.59 [6.33] 92.01 [5.67] 45.29 [9.95] 63.58 [8.68]
CK1 0.98 [0.14] 85.05 [8.21] 87.85 [7.94] 62.61 [11.20] 76.30 [8.58]
RGC 1.02 [0.19] 85.30 [6.00] 87.53 [6.86] 50.43 [5.36] 66.70 [5.38]
PKL 1.07 [0.12] 88.45 [3.92] 91.53 [4.01] 43.55 [6.34] 60.90 [5.82]
Unclassified 1.06 [0.11] 82.50 [14.84] 88.92 [9.30] 35.12 [7.76] 58.10 [3.93]
Table 1.  Pairwise comparisons of Schistosoma haematobium (Sh) kinase sequences with orthologs in 
S. mansoni (Sm) and human. Average length ratios, identity and similarity values are indicated. Amino 
acid sequence conservation between S. haematobium and S. mansoni was observed for all kinase groups. 
Predicted sequences had very similar lengths. The comparison with human homologs showed moderate to 
low identities and similarities. Average and standard deviation [SD] values were calculated based on the 
number of predicted S. haematobium sequences in each kinase group. aCMGC = Cyclin-dependent kinases 
(CDKs), mitogen-activated protein kinases (MAP kinases), glycogen synthase kinases (GSKs) and CDK-like 
kinases; CAMK = Ca2+/calmodulin-dependent kinases; AGC = Nucleoside-regulated kinases; TK = Tyrosine 
kinases; STE = MAPK cascade kinases; TKL = Tyrosine kinase-like kinases; CK1 = Casein kinase 1 kinases; 
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Name Kinase classification
Novel (Nua) kinase family CAMK/CAMKL/NUAK
MAPK-integrating or -interacting kinase CAMK/MAPKAPK/MNK
Testis-specific serine/threonine kinase CAMK/TSSK
RSK-like kinase AGC/RSKL
Mitogen- and stress-activated protein kinase AGC/RSK/MSK
RSK-related kinase AGC/RSKR
Yet another novel kinase AGC/YANK
Budding uninhibited by benzimidazoles kinase OTHER/BUB
New kinase family 1 OTHER/NKF1
Anaplastic lymphoma kinase TK/ALK
Discoidin domain receptor kinase TK/DDR
IL1 receptor-associated kinase TKL/IRAK
Serine/threonine-like kinase STE/STE20/STLK
Eukaryotic elongation factor 2 kinase ATYPICAL/ALPHA/EEF2K
Bromodomain-containing kinases ATYPICAL/BRD
Pyruvate dehydrogenase kinase ATYPICAL/PDHK
Phosphatidylinositol 3 kinase-related kinase ATYPICAL/PIKK
Right open reading frame kinase 3 ATYPICAL/RIO/RIO3
TATA-binding protein-associated factor 1 ATYPICAL/TAF1
Table 2.  Kinase families and subfamilies absent from the kinomes of Schistosoma haematobium and 
S. mansoni (Lophotrophozoa; Protostomia). Members of these families and subfamilies are found in both 
Ecdysozoa (Protostomia) and Deuterostomia.
Figure 3. Functional annotation and levels of transcription of Schistosoma haematobium kinase genes. 
(a) All kinase genes transcribed in different sexes/developmental stages (male, female and egg). (b) Top 
10% of transcribed kinase genes. Proteins inferred from these transcripts were associated with biochemical 
pathways. Numbers of inferred sequences in the respective functional category are indicated in parentheses 
for each sex/developmental stage.
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stages (TPM female: 2.64; TPM male: 9.80); Sh_Smp_017900.1 was most highly transcribed in the egg 
stage (TPM: 50.97), but was also transcribed at varying levels in both adult stages (TPM female: 5.32; 
TPM male: 23.57).
Although most kinase genes were transcribed in all developmental stages of S. haematobium (Figs 3a 
and 4), there were differences in transcription levels, depending on their functional category (Fig. 3b). 
Notably, almost twice as many genes of kinases associated with cell growth and death were highly tran-
scribed in the egg stage compared with either gender of the adult stage. In addition, kinase genes asso-
ciated with cell motility were more abundantly transcribed in the male adult. We also found increased 
levels of transcription for kinase genes associated with environmental adaptation and the sensory system 
in the egg and male adult compared with the female adult stage.
Druggable kinases and their prioritisation. Following the transcriptional analysis, we prioritised 
S. haematobium kinases as potential drug targets. First, we inferred the essentiality of S. haematobium 
kinase genes based on lethal gene knock-down or knock-out phenotypes linked to one-to-one orthologs 
in C. elegans, D. melanogaster and/or Mus musculus (Supplementary Table 3). In total, 219 of 269 (81%) 
S. haematobium kinases matched orthologs inferred to be associated with lethal phenotypes in at least 
one of the three organisms (Supplementary Table 3). Of these 219 kinases, 57 mapped (at amino acid 
level) to unique chokepoints in key biological pathways (Supplementary Table 3). Of these 57 kinases, 40 
were predicted to bind chemical ligands listed in Kinase SARfari and DrugBank, 11 of which were pres-
ent in both databases (Supplementary Tables 4–5). These 40 kinases represented all recognised groups, 
except RGC, and had human orthologs, some of which related to the nervous system, development and/
or cancer (Fig. 5b).
Figure 4. Venn diagram indicating the number of kinase genes selectively transcribed in the three 
developmental stages of Schistosoma haematobium studied. A total of 214 kinase genes were constitutively 
transcribed in all three developmental stages. Of the 274 coding regions, 16 were not transcribed. Kinase 
families/subfamilies assigned to transcribed kinase genes are indicated (boxed).
Figure 5. Kinases prioritised as targets in Schistosoma haematobium and associated pathways.  
(a) Numbers of predicted targets in individual kinase groups. Kinases that have already been investigated  
or prioritised in S. mansoni are indicated. (b) Pathway associations of prioritised targets.
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Then, we showed that genes encoding these 40 kinases were transcribed in both adult and egg stages 
(n = 38), and that two (i.e. A_06570 and A_07448) were specific to adults (Supplementary Table 2). 
Amongst them were two casein kinases (A_08312.1 and Sh_Smp_099030.1) with >90% sequence similar-
ity to human orthologs; four other kinases in this group (i.e. A_03569 (FAK), A_00551 (GCN2), m.56516 
(RAF) and A_03539 (CHK1)) had ≤ 50% sequence similarity to human counterparts (Supplementary 
Table 1).
Of the 40 prioritised kinases, tyrosine kinases were the most highly represented group (n = 9), includ-
ing a fibroblast growth factor receptor (Sh-FGFR-A), two insulin receptors (Sh-IR-1 and Sh-IR-2) and 
kinases SYK (Sh-TK4) and FYN (Sh-TK5), orthologs of which have been experimentally evaluated 
as drug targets in one or more schistosomes other than S. haematobium13,29,32,37–39. Two other targets, 
namely Sh-Akt (AGC group) and A_04108.1 (CMGC group; GSK family), were inferred, both of which 
have also been predicted to be promising drug targets in S. mansoni40,41 (Fig. 5a).
Taken together, we predicted that all 40 essential kinases represent targets, and therefore interrogated 
key databases for chemicals. We identified 42 drugs predicted to bind one or more of these targets, 17 
of which are already approved by the FDA for the treatment of cancers or other diseases of humans 
(Table  3). These 17 drugs include four ABL kinase inhibitors (imatinib42, dasatinib43, bosutinib44 and 
ponatinib45), one JAK kinase inhibitor (tofacitinib), one GSK3 inhibitor (lithium carbonate), one protein 
kinase C inhibitor (ingenol mebutate) and 10 other drugs that inhibit multiple (receptor) kinases.
Discussion
Here, we established an integrated bioinformatic pipeline to identify, classify and curate full-length 
kinase sequences encoded in the genome of S. haematobium for subsequent comparison with orthologs 
in S. mansoni and humans. This workflow enabled high-confidence predictions of anti-schistosome drug 
targets and compounds, and should be applicable to various schistosome species and, following modifi-
cation, also to other flatworms as well as roundworms. In the future, we propose to gradually enhance 
the workflow by integrating tools for the prediction of binding sites of ligands, structural comparisons of 
prioritised targets and/or comparative analyses of parasite and host kinases into this pipeline.
In most previous studies, the identification of kinase sequences has relied on searches using HMMs 
from databases such as Pfam46 or Kinomer47, or position-specific scoring matrices (PSSMs)48. However, 
the combination of several of these methods can achieve enhanced predictions and classification com-
pared with a single method. The program Kinannote uses such a combined approach, thereby increasing 
sensitivity and precision for kinase identification49, and was thus employed by us to produce a draft 
kinome in the first step of our workflow. Subsequently, an orthology-based approach50, using the pub-
lished kinome33 and draft genome of S. mansoni51 as a reference, identified pairs of kinase orthologs, 
which facilitated the improvement of gene models for both schistosomes. This step also increased the 
number of kinases identified in S. haematobium by 17%, and their classification into families/subfamilies 
by 30%. Independent phylogenetic analyses verified the pairs of orthologs and functional subfamilies. 
Since the construction of reliable phylogenetic trees requires meticulous alignment of homologous char-
acters, we restricted multiple alignments to the catalytic domains of kinases, because some sequence 
regions external to the catalytic domain can vary considerably. Phylogenetic trees calculated from these 
alignments can be used to sub-classify kinases, as sequence divergence in catalytic domains of kinases is 
recognised to reflect variation of function and/or mode of regulation of protein kinases23,52. The bound-
aries of kinase catalytic domains, such as Pkinase (Pfam identifier PF00069) or Pkinase_Tyr (Pfam iden-
tifier PF07714), are usually defined by HMMs. However, the sequences used to construct these two 
HMMs (n = 54 and n = 145, respectively) did not represent any lophotrochozoans, and thus, might not 
accurately represent the catalytic kinase domains of trematodes, which are clearly evolutionarily very dis-
tinct from those of Ecdysozoa and Deuterostomia53. In contrast to the alignment made using these Pfam 
HMMs, we obtained an improved alignment of homologous characters (with less gaps) by constructing 
a HMM from high-confidence kinase predictions for four trematode species.
Using the present bioinformatic workflow, we identified 269 full-length kinases that represent the 
kinome of S. haematobium. An assessment of transcription levels revealed transcription of 258 sequences, 
214 (79.5%) of which were constitutively transcribed in all developmental stages/sexes studied, indicating 
essential roles for these kinases in signalling processes throughout the parasite’s life cycle. This state-
ment is supported by the constitutive transcription of 83 of the 108 kinase genes (77%) assigned to the 
functional categories ‘signal transduction’ and/or ‘cell communication’. In contrast, only 11 (10%) kinase 
genes assigned to these general categories had variable transcription profiles. Although a small number of 
kinase sequences identified (n = 16; < 6%) were not transcribed in either the egg or adult stage, they are 
likely to be transcribed in other developmental stages (including the miracidium, cercaria and/or schis-
tosomulum) not investigated here. The validity of these sequences was supported by pairwise orthologs 
in S. mansoni that are transcribed in the cercarial and/or schistosomule stages51.
Sex-specifically transcribed kinase genes were more frequently assigned to specialised functional 
categories; among them was the male-specifically transcribed testis-expressed gene 14 (Tex14, Sh_
Smp_131630.1), which we hypothesize is critical for chromosome segregation associated with mito-
sis and meiosis during spermatogenesis. This proposal is supported by findings in mice, showing that 
Tex14 is highly expressed during spermatogenesis, and localises to intracellular bridges of germ cells, 
where it plays an integral role in the establishment and maintenance of male fertility54,55. Other evidence 
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Name or code of compound
Number 
of target 
kinases Indicated for treatment of
Status of 
approval
AG-13736 (axitinib) 1 Cancer A
Dasatinib 32 Cancer A
Pazopanib 30 Cancer A
Erlotinib 30 Cancer A
Imatinib 30 Cancer A
Gefitinib 30 Cancer A
Sorafenib 32 Cancer A
Sunitinib 32 Cancer A
Vandetanib 30 Cancer A
CP-690550 (tofacitinib) 30 Rheumatoid arthritis, psoriasis, inflammatory bowel disease A
Bosutinib 4 Cancer A
Cabozantinib 1 Cancer A
Ingenol mebutate 1 Cancer, actinic keratosis A
Ponatinib 3 Cancer A
Regorafenib 2 Cancer A
Trametinib 2 Cancer A
Lithium carbonate 1 Bipolar disorder A
ABT-869 (linifanib) 31 Cancer III
Vatalanib 30 Cancer III
AMG-706 (motesanib) 30 Cancer III
PD-184352 4 Cancer II
PHA-739358 (danusertib) 6 Cancer II
Seliciclib 30 Cancer II
SNS-032 30 Cancer I
Fasudil 4 Cerebral vasospasm, pulmonary hypertension II
Ruboxistaurin 33 Diabetic retinopathy III
CHEMBL1173486 2 Unknown N/A
CHEMBL1230122 1 Unknown N/A
CHEMBL150504 1 Unknown N/A
AT7519 1 Cancer II
AZD2171 (cediranib) 1 Cancer III
CYC116 1 Cancer I
Ellagic acid 2 Cancer N/A
XL228 1 Cancer I
XL518 (cobimetinib) 2 Cancer III
XL820 1 Cancer II
XL844 2 Cancer I
XL880 (foretinib) 1 Cancer II
XL999 2 Cancer II
CEP-1347 1 Asthma, Parkinson’s disease III
KC706 1 Rheumatoid arthritis, psoriasis, inflammatory bowel disease II
TG100801 1 Macular degeneration, diabetic retinopathy II
Table 3.  List of prioritised chemical compounds as drug candidates against Schistosoma haematobium. 
For each compound, the number of target kinases, its indicated therapeutic use(s) and the status of FDA 
approval for use in humans are given (A = approved; I, II or III = phase of clinical trial). Additional 
information and chemical structures are given in Supplementary Tables 4–6.
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from a study of human cells lines shows that TEX14 is regulated by the kinase Plk-1 and is crucial for 
kinetochore-microtubule attachment during mitosis56.
A second gene encoding a protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK; 
A_03220) was transcribed exclusively in female and egg stages of S. haematobium. The human ortholog 
of this kinase phosphorylates the eukaryotic translation initiation factor 2 alpha (eIF2α ) and mediates 
the response to endoplasmic reticulum (ER) stress (represented by an accumulation of misfolded or 
unfolded proteins in the ER) which, among other factors, is induced by glucose deprivation57,58 and/or an 
excessive requirement for proteins59. The transcription of this additional, stress-mitigating kinase in eggs 
and female worms might thus be a mechanism to cope with increased ER stress due to the energy- and 
protein-demanding processes of reproduction, which are sustained by glucose metabolism. This specific 
transcription might also relate to stress on female worms, induced by separating them from their male 
partner (on which they rely, in terms of nutrient supply, such as sugar uptake from the host)60 prior to 
RNA-sequencing.
A third kinase gene encoding a myotonic dystrophy protein kinase (A_05067) of the DMPK family 
was transcribed exclusively in the egg stage of S. haematobium. Since different muscle types are already 
established in the miracidium within the egg, and a transformation of these muscle structures takes 
place during metamorphosis from sporocysts to cercariae61, we propose that this kinase-encoding gene 
is specifically transcribed in the miracidium in the egg, and is involved in muscle development and/or 
locomotion/motility. Evidence from other invertebrates, such as D. melanogaster, shows that DMPKs are 
involved in establishing correct muscle morphology and functionality in third instar larvae62. This aspect 
warrants further exploration when RNA-sequencing data for the miracidium stage of S. haematobium 
become available.
Comparative analysis showed that the S. haematobium kinome contains all recognised eukaryotic 
kinase groups, including 79 of the 144 (55%) subfamilies found in other metazoans studied16,63. The 
S. haematobium kinome has approximately half of the 518 kinases found in humans15 and has a similar 
number to that (n = 438) of the C. elegans kinome, to the exclusion of known specific expansions in this 
free-living nematode16,63. Nonetheless, we did not detect any members of 19 kinase families/subfamilies 
present in C. elegans, D. melanogaster or H. sapiens. The lack of evidence for kinases of these families/
subfamilies, including RIO3 (which has been lost from numerous flatworms64), suggests their absence 
from schistosomes or a substantial diversification of their sequences that precluded their identification. 
Since there are presently no curated kinomes for flatworms other than S. haematobium and S. mansoni, 
it is not known whether such kinase families or subfamilies have been lost from all lophotrochozoans or 
only from schistosomes during evolution. A preliminary exploration of the flatworms Clonorchis sinensis, 
Opisthorchis viverrini and Fasciola hepatica (Stroehlein et al., unpublished) suggests that these families 
and subfamilies (except the PIKK family) are absent from lophotrochozoans. Future studies should focus 
on defining and curating the kinomes of a range of socioeconomically important parasitic flatworms 
and roundworms (nematodes), in order to undertake detailed comparative analyses, explore kinome 
evolution and investigate contractions and expansions of particular kinase groups in relation to worm 
phylogeny as well as biology.
The global comparison of the kinomes of S. haematobium and its close relative, S. mansoni, did not 
detect any major expansions or contractions in kinase groups, families or subfamilies, but did reveal 
two kinase genes of the CMGC group (ERK7 and DYRK2 subfamilies) that are present exclusively in 
the former species. Given the quality of the draft genome and transcriptome of S. mansoni, there is only 
a remote possibility that these two genes were not detected. It is more plausible that they are indeed 
uniquely present in S. haematobium and encode kinases that may relate indirectly to this pathogen’s 
unique biology and site predilection in the human host. Published evidence indicating that ERKs are 
involved in parasite-host interactions65,66 supports this hypothesis. Although very little is known about 
the function of the second S. haematobium-specific kinase (DYRK2), in human and murine cell lines, 
a DYRK homolog interacts with the MAPK kinase MKK3 (an upstream activator of p38), which is 
involved in a growth factor-mediated signalling pathway67. The fact that both S. haematobium-specific 
kinases are part of receptor-activated signalling pathways advocates a role in pathogen-host interactions, 
as has been suggested previously for other receptor kinase pathways68,69.
Despite this difference of two kinases, the comparison of the kinomes of S. haematobium and S. mansoni 
showed a relatively high level of conservation of kinase sequences. Although such conservation has been 
reported previously for small numbers of kinases32,38,70, here we report the first global comparison of 
these kinomes. The conservation between the kinomes of the two most medically important species of 
schistosomes is considered to provide opportunities for the repurposing of existing, safe drugs against 
both species25. Thus, we focused on 40 S. haematobium kinase genes with (relatively) conserved orthologs 
in S. mansoni and S. japonicum (not shown) as well as human, whose gene products are inferred to be 
essential and to bind drugs available for treating human diseases.
A functional annotation of these 40 kinases showed that 37.5% (n = 15) were linked to human ort-
hologs that are involved in cancer pathways, and a similar number of kinases (n = 14; 35%) were linked 
to roles in the immune system (Fig. 5b). Based on these findings, we suggest that associated anti-cancer/
anti-inflammatory compounds should now be assessed as to their ability to disrupt normal schistosome 
growth, development and/or viability in vitro. In this context, a recent study has shown that blood com-
ponents (such as serum albumin and α -1 acid glycoprotein) impede the deleterious effect of the drug 
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imatinib on schistosomes in vitro, which should be considered in the experimental design of in vitro or 
in vivo experiments71.
A list of compounds (Table  3) revealed promising candidates for repurposing as schistosome 
kinase inhibitors. Many of these compounds have been predicted to target multiple kinases (targeted 
poly-pharmacology), a property that can increase the deleterious effect of a drug, thereby overcom-
ing limited efficacy (due to redundancies in signalling pathways) associated with some single-targeted 
drugs72,73. Among the selected compounds were the anti-cancer drugs imatinib and dasatinib, the latter 
of which is assumed to target the Src/Fyn kinase SmTK5 in S. mansoni13. The orthologous kinase in 
S. haematobium (Sh-TK5) is one of the 40 prioritised targets in this study. Other selected targets of par-
ticular interest (Fig. 5a) include a Syk kinase (Sh-TK4), four receptor kinases (Sh-IR1, Sh-IR2, Sh-FGFR-A 
and B_00871), two members of the AGC group (Sh-Akt and A_01385) and a GSK3 kinase (A_04108.1). 
These kinases have either already been computationally predicted as drug targets in S. mansoni, or there 
is some experimental evidence indicating that orthologs in S. mansoni are essential and/or can be inhib-
ited in vitro13,27,29,32,37,38,40,41,65,68, which lends additional support to our predictions. Furthermore, we pre-
dicted 32 additional kinases as potential targets for which no experimental information is yet available 
for schistosomes, including a TTK kinase (Sh_Smp_171610.1) and an eIF2α kinase ortholog (A_00551). 
Sh_Smp_171610.1 is an ortholog of a human kinetochore kinase, also known as Mps1 (Monopolar spin-
dle 1), which plays an essential role in the spindle assembly checkpoint (SAC) pathway74. The priori-
tised eIF2α kinase ortholog is involved in mediating stress-response pathways, and several members of 
this kinase family are essential in Plasmodium falciparum (malaria parasite)75. Taken together, the high 
sequence similarity between schistosome kinases and the availability of kinase inhibitors for human ort-
hologs offer great prospect with regard to the development of new anti-schistosome drugs.
In addition to the conserved kinase complement, there is also considerable merit in exploring selec-
tive kinase targets, namely those that are specific to schistosomes but absent from the mammalian host. 
For instance, the two genes encoding VKRs are specific to schistosomes and other Protostomia32,76, but 
absent from humans. Some functional studies of S. mansoni have shown that the compound tryphostin 
AG1024 kills schistosomula and adults in vitro32,77 by targeting schistosome VKRs and IRs. Given the 
sequence conservation of VKRs and IRs between S. haematobium and S. mansoni (97.3% and 93.8% 
similarity, respectively), this compound is likely to also kill the former species. In the context of identi-
fying further schistosome-specific targets, four pairs of unclassified schistosome kinases identified here 
(Supplementary Table 1) were of interest, as they exhibited substantially lower sequence similarity to 
their human orthologs compared with S. mansoni orthologs. Three of these kinase-encoding genes were 
transcribed at varying levels in at least one of the sexes of the adult stage. We suggest that these results 
might assist in designing inhibitors for schistosomes, particularly if the premise is to target less conserved 
structural regions in a kinase outside of the conserved catalytic domain. This hypothesis warrants testing.
The curated set of kinases for S. haematobium as well as for its close relative, S. mansoni, might provide 
a stepping stone to fundamental studies of the biology of selected kinases in these worms. For instance, 
gene knockdown experiments by double-stranded RNA interference (RNAi)78 could be conducted on 
adult worms to validate the essentiality of subsets of kinases as drug targets in schistosomes. Combined 
with transcriptomic, proteomic and metabolomic investigations79–81 of treated versus untreated schisto-
somes, such studies could provide insights into the biological (e.g., signalling) pathways affected in the 
schistosome and also verify the specific knockdown of kinase genes and gene products. Moreover, in a 
similar manner, chemical knockdown experiments could confirm the specificity of the predicted and 
prioritised ligands in vitro82. Concordance between RNAi and chemical knockdown results would then 
provide confidence regarding the bioinformatic drug target/drug predictions made. Subsequently, com-
pounds for which one or multiple targets have been validated and that have shown efficacy in vitro could 
then be investigated further in a hit-to-lead phase. At this point, chemical analogs could be produced 
to optimise target selectivity and minimize side effects on the host organism. Selected chemicals with 
specific binding to a kinase target but with limited selectivity (e.g., because of activity in mammalian host 
cells) might still serve as probes14 to explore kinase biology in the parasite.
In conclusion, we believe that the present bioinformatic investigation represents a step forward in 
the characterisation and curation of worm kinomes. The concordance in results between S. mansoni and 
S. haematobium (Fig. 2; Supplementary Table 1) as well as known lethal/adverse effects of some inhibitors 
against S. mansoni kinases13,27,29,32,37,38,40,41,65,68 suggest that some of our target and drug predictions are 
promising. However, we acknowledge that the prediction of drug targets and associated ligands rep-
resents a humble beginning to an often long and challenging route to validate new chemical entities 
(NCEs), to assess them in a preclinical context by administration, distribution, metabolism, excretion 
and toxicity (ADMET) testing83–85, and, via clinical trials (phases I-III; http://www.phrma.org/innova-
tion/clinical-trials)86, to develop one or more safe, effective and specific anti-schistosomal drugs. We 
hope that our bioinformatic pipeline will assist, at least in part, at the very beginning of this long and 
expensive discovery and development process.
Methods
Defining the S. haematobium kinome. We predicted, curated and annotated the protein kinase 
complement encoded in the published draft genome87 using an integrated bioinformatic pipeline in six 
steps (Fig. 1):
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(1) First, we identified ePKs and PKLs of S. haematobium using the program Kinannote49 employing the 
-m (metazoan) option. Predicted kinase sequences were then classified according to group, family 
and/or subfamily16,63. Sequences that could not be unequivocally classified using this approach were 
retained for subsequent curation.
(2) Orthologous kinase sequences from both S. haematobium and S. mansoni were predicted by pair-
wise sequence comparison using the program OrthoMCL50, employing publicly accessible (Schis-
toDB v.3.0; http://schistodb.net/schisto/ and GeneDB v.5.2; http://www.genedb.org/) genomic and 
transcriptomic datasets51,87,88. Amino acid sequences that grouped with classified kinases, but were 
not predicted to be kinases using Kinannote, were added to a kinase group, family or subfamily based 
on their respective orthologous sequence (in the heterologous species) and included in subsequent 
analyses.
(3) Then, we exhaustively searched all of the genomic and transcriptomic data available for S. haema-
tobium and S. mansoni, to be able to complement any incomplete sequences and also to retrieve 
kinase-encoding sequences that had not been predicted previously for either or both schistosome 
species. If a full-length ortholog could not be inferred for the heterologous species, the kinase amino 
acid sequence was aligned to the genomic scaffold coding for the incomplete gene using the program 
BLAT89. This genomic region was then exhaustively searched for a full-length orthologous coding 
domain using the program Exonerate90 employing the multi-pass suboptimal alignment algorithm 
and the protein2genome:bestfit model. Refined gene predictions and protein translations were named 
according to their ortholog identifier (e.g., Sh_Smp_123456.1 and Smp_A_12345).
(4) To increase the sensitivity of identification of kinase domains of schistosomes, we constructed HMMs 
for individual kinase groups based on the catalytic domains of high-confidence trematode kinase se-
quences (assigned to a subfamily by Kinannote) using the program HMMER v.3.1b1 (http://hmmer.
janelia.org/). These HMMs were constructed using the inferred proteomic datasets of S. japonicum, 
C. sinensis, O. viverrini and F. hepatica91–94, and were then employed to query kinase sequences of 
individual groups of S. haematobium and S. mansoni and to identify catalytic kinase domains.
(5) The catalytic domain sequences of all predicted kinases representing individual groups were aligned 
using the program MAFFT v.6.864b, employing the L-INS-i option95. Alignments were improved 
using the program MUSCLE v.3.7 (-refine option)96 and by subsequent manual adjustment, to opti-
mise the alignment of homologous characters. The aligned sequences were then subjected to Bayesian 
inference (BI) analysis in the program MrBayes v.3.2.2 (ref.  97). Posterior probabilities (pp) were 
calculated, as recommended, using a mixture of models with fixed rate matrices, generating 1,000,000 
trees and sampling every 100th tree. The initial 25% of trees were discarded as burn-in, and the 
others were used to construct a majority rule tree. Phylogenetic trees were drawn using the program 
FigTree v.1.4.1 (http://tree.bio.ed.ac.uk/software/figtree/).
(6) Curated kinase sequences were functionally annotated by searching the databases Swiss-Prot (data-
base release 01/2014)98 and KEGG BRITE (database release 03/2014)99 using BLASTP v.2.2.28+ 
(ref.  100) and an e-value cut-off of 10−05. Pfam domains and PANTHER families were predicted 
using the program InterProScan v.5–44.0 (ref. 101). In addition, sequence identities and similarities 
to S. mansoni and human kinase homologs (sequences accessed from KinBase, http://kinase.com/
kinbase/FastaFiles/) were determined for S. haematobium kinases by pairwise comparison using the 
program EMBOSS Matcher v.6.3.1 (ref. 102).
Transcription analysis. We assessed transcription in male and female adults as well as eggs of S. hae-
matobium using publicly available RNA-seq data87. Data were filtered using the program Trimmomatic103 
and aligned to the final sequences encoding kinases using Bowtie v.2.1.0 (ref. 104). Levels of transcription 
(numbers of transcripts per million, TPMs) were calculated using the software package RSEM v.1.2.11 
(ref.  105). Kinase genes were considered as transcribed if at least 5 read pairs mapped to their coding 
regions and they had a TPM of > 0. For each kinase gene, a relative measure of transcription was inferred 
by ranking individual genes from S. haematobium by their TPM values. The top and bottom 10% of 
transcribed genes were defined as being highly and lowly transcribed, respectively.
Drug target prediction and prioritisation. To assess the druggability of individual predicted 
kinases and to prioritise them as potential targets in S. haematobium, essentiality was inferred by select-
ing S. haematobium proteins homologous (BLASTP; e-value ≤ 10−5) to C. elegans, D. melanogaster 
and/or M. musculus kinases with a lethal phenotype upon gene perturbation - listed in WormBase106, 
FlyBase107 and MGI108. Essential kinases were considered to represent metabolic chokepoints if only one 
gene was assigned to one KEGG orthologous gene (KO) term for a KEGG pathway. These kinases were 
then matched to homologous kinase sequences in the databases Kinase SARfari109 and DrugBank v.3.0 
(ref.  110) using PSI-BLAST v.2.2.26+ employing an e-value cut-off of 10−30 (ref.  111). If both query 
and target sequence had the same kinase classification (using Kinannote), the sequence in the database 
had one or more ligands that met the Lipinski rule-of-five112 and was flagged as “medicinal chemistry 
friendly”, salient information on associated ligands (chemicals or small molecules) was extracted from 
the two databases and used to assess the druggability of the target. Prioritised kinases predicted to bind 
compounds approved by the FDA for use in humans or assessed in clinical trials, as indicated in Kinase 
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SARfari (https://www.ebi.ac.uk/chembl/sarfari/kinasesarfari), were considered to have potential as drug 
targets. Kinases with entries in DrugBank were prioritised as drug targets if at least one associated small 
molecule (with a description of its properties) was found in this database.
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